BACE1 and Alzheimer disease: Collectively, optimal clinical trials should be designed by initiating interventions with selective BACE1 inhibitors at the earliest preclinical AD stage, utilizing very sensitive cognitive paradigms and relevant biomarkers for efficacy, and targeting safe levels of reduction in β-secretase activity (~50% or lower) supported by safety biomarker assessments to avoid potential side effects.